| Dr Gary C Pien, MD, PHD | |
|
1 Diamond Hill Rd, Berkeley Heights, NJ 07922-2104 | |
| (908) 273-4300 | |
| Not Available |
| Full Name | Dr Gary C Pien |
|---|---|
| Gender | Male |
| Speciality | Allergy/immunology |
| Experience | 21 Years |
| Location | 1 Diamond Hill Rd, Berkeley Heights, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1841404530 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207K00000X | Allergy & Immunology | 25MA08470800 (New Jersey) | Primary |
| 208000000X | Pediatrics | 25MA08470800 (New Jersey) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Overlook Medical Center | Summit, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Summit Medical Group Pa | 5395642276 | 1253 |
News Archive
Trius Therapeutics, Inc. has announced that it initiated its first Phase 1 clinical trial of TR-701, an antibacterial drug candidate intended for treatment of patients with serious Gram-positive bacterial infections, including those caused by MRSA and other drug-resistant strains.
Medical professionals have announced the need to change treatment of elderly patients in cardiac intensive care units.
Researchers at the Pontif-cia Universidade Cat-lica do Paran- and Instituto Carlos Chagas have evaluated the therapeutic potential of purified and expanded CD133+ cells human umbilical cord blood (HUCB)-derived in treating myocardial infarction by intramyocardially injecting them into a rat model. Patients who have high cardiovascular risks have fewer endothelial progenitor cells (EPCs) and their EPCs exhibit greater in vitro senescence.
New research published in the Journal of Leukocyte Biology, shows that the development of white matter in the mouse brains is delayed when they are exposed to chronic low oxygen levels shortly after birth.
› Verified 9 days ago
| Entity Name | Summit Medical Group Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942254347 PECOS PAC ID: 5395642276 Enrollment ID: O20031218000011 |
News Archive
Trius Therapeutics, Inc. has announced that it initiated its first Phase 1 clinical trial of TR-701, an antibacterial drug candidate intended for treatment of patients with serious Gram-positive bacterial infections, including those caused by MRSA and other drug-resistant strains.
Medical professionals have announced the need to change treatment of elderly patients in cardiac intensive care units.
Researchers at the Pontif-cia Universidade Cat-lica do Paran- and Instituto Carlos Chagas have evaluated the therapeutic potential of purified and expanded CD133+ cells human umbilical cord blood (HUCB)-derived in treating myocardial infarction by intramyocardially injecting them into a rat model. Patients who have high cardiovascular risks have fewer endothelial progenitor cells (EPCs) and their EPCs exhibit greater in vitro senescence.
New research published in the Journal of Leukocyte Biology, shows that the development of white matter in the mouse brains is delayed when they are exposed to chronic low oxygen levels shortly after birth.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Gary C Pien, MD, PHD 1 Diamond Hill Rd, Berkeley Heights, NJ 07922-2104 Ph: (908) 273-4300 | Dr Gary C Pien, MD, PHD 1 Diamond Hill Rd, Berkeley Heights, NJ 07922-2104 Ph: (908) 273-4300 |
News Archive
Trius Therapeutics, Inc. has announced that it initiated its first Phase 1 clinical trial of TR-701, an antibacterial drug candidate intended for treatment of patients with serious Gram-positive bacterial infections, including those caused by MRSA and other drug-resistant strains.
Medical professionals have announced the need to change treatment of elderly patients in cardiac intensive care units.
Researchers at the Pontif-cia Universidade Cat-lica do Paran- and Instituto Carlos Chagas have evaluated the therapeutic potential of purified and expanded CD133+ cells human umbilical cord blood (HUCB)-derived in treating myocardial infarction by intramyocardially injecting them into a rat model. Patients who have high cardiovascular risks have fewer endothelial progenitor cells (EPCs) and their EPCs exhibit greater in vitro senescence.
New research published in the Journal of Leukocyte Biology, shows that the development of white matter in the mouse brains is delayed when they are exposed to chronic low oxygen levels shortly after birth.
› Verified 9 days ago